Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The artificial sweetener erythritol and cardiovascular event risk

M. Witkowski, I. Nemet, H. Alamri, J. Wilcox, N. Gupta, N. Nimer, A. Haghikia, XS. Li, Y. Wu, PP. Saha, I. Demuth, M. König, E. Steinhagen-Thiessen, T. Cajka, O. Fiehn, U. Landmesser, WHW. Tang, SL. Hazen

. 2023 ; 29 (3) : 710-718. [pub] 20230227

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23003918

Grantová podpora
P01 HL147823 NHLBI NIH HHS - United States
R01 HL103866 NHLBI NIH HHS - United States

E-zdroje NLK Online Plný text

ProQuest Central od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 2000-01-01 do Před 1 rokem

Odkazy
PubMed 36849732
DOI 10.1038/s41591-023-02223-9
Knihovny.cz E-zdroje

Artificial sweeteners are widely used sugar substitutes, but little is known about their long-term effects on cardiometabolic disease risks. Here we examined the commonly used sugar substitute erythritol and atherothrombotic disease risk. In initial untargeted metabolomics studies in patients undergoing cardiac risk assessment (n = 1,157; discovery cohort, NCT00590200 ), circulating levels of multiple polyol sweeteners, especially erythritol, were associated with incident (3 year) risk for major adverse cardiovascular events (MACE; includes death or nonfatal myocardial infarction or stroke). Subsequent targeted metabolomics analyses in independent US (n = 2,149, NCT00590200 ) and European (n = 833, DRKS00020915 ) validation cohorts of stable patients undergoing elective cardiac evaluation confirmed this association (fourth versus first quartile adjusted hazard ratio (95% confidence interval), 1.80 (1.18-2.77) and 2.21 (1.20-4.07), respectively). At physiological levels, erythritol enhanced platelet reactivity in vitro and thrombosis formation in vivo. Finally, in a prospective pilot intervention study ( NCT04731363 ), erythritol ingestion in healthy volunteers (n = 8) induced marked and sustained (>2 d) increases in plasma erythritol levels well above thresholds associated with heightened platelet reactivity and thrombosis potential in in vitro and in vivo studies. Our findings reveal that erythritol is both associated with incident MACE risk and fosters enhanced thrombosis. Studies assessing the long-term safety of erythritol are warranted.

000      
00000naa a2200000 a 4500
001      
bmc23003918
003      
CZ-PrNML
005      
20230425140955.0
007      
ta
008      
230418s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41591-023-02223-9 $2 doi
035    __
$a (PubMed)36849732
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Witkowski, Marco $u Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA $1 https://orcid.org/0000000269525038
245    14
$a The artificial sweetener erythritol and cardiovascular event risk / $c M. Witkowski, I. Nemet, H. Alamri, J. Wilcox, N. Gupta, N. Nimer, A. Haghikia, XS. Li, Y. Wu, PP. Saha, I. Demuth, M. König, E. Steinhagen-Thiessen, T. Cajka, O. Fiehn, U. Landmesser, WHW. Tang, SL. Hazen
520    9_
$a Artificial sweeteners are widely used sugar substitutes, but little is known about their long-term effects on cardiometabolic disease risks. Here we examined the commonly used sugar substitute erythritol and atherothrombotic disease risk. In initial untargeted metabolomics studies in patients undergoing cardiac risk assessment (n = 1,157; discovery cohort, NCT00590200 ), circulating levels of multiple polyol sweeteners, especially erythritol, were associated with incident (3 year) risk for major adverse cardiovascular events (MACE; includes death or nonfatal myocardial infarction or stroke). Subsequent targeted metabolomics analyses in independent US (n = 2,149, NCT00590200 ) and European (n = 833, DRKS00020915 ) validation cohorts of stable patients undergoing elective cardiac evaluation confirmed this association (fourth versus first quartile adjusted hazard ratio (95% confidence interval), 1.80 (1.18-2.77) and 2.21 (1.20-4.07), respectively). At physiological levels, erythritol enhanced platelet reactivity in vitro and thrombosis formation in vivo. Finally, in a prospective pilot intervention study ( NCT04731363 ), erythritol ingestion in healthy volunteers (n = 8) induced marked and sustained (>2 d) increases in plasma erythritol levels well above thresholds associated with heightened platelet reactivity and thrombosis potential in in vitro and in vivo studies. Our findings reveal that erythritol is both associated with incident MACE risk and fosters enhanced thrombosis. Studies assessing the long-term safety of erythritol are warranted.
650    _2
$a lidé $7 D006801
650    12
$a sladidla $x škodlivé účinky $7 D013549
650    _2
$a prospektivní studie $7 D011446
650    _2
$a erythritol $x farmakologie $7 D004896
650    12
$a infarkt myokardu $7 D009203
650    _2
$a srdce $7 D006321
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Nemet, Ina $u Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA $1 https://orcid.org/0000000206577121
700    1_
$a Alamri, Hassan $u Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA $u Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia $1 https://orcid.org/0000000343130940
700    1_
$a Wilcox, Jennifer $u Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA $1 https://orcid.org/0000000162771079
700    1_
$a Gupta, Nilaksh $u Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA
700    1_
$a Nimer, Nisreen $u Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA
700    1_
$a Haghikia, Arash $u Department of Cardiology, Angiology and Intensive Care, German Heart Center of Charité, Campus Benjamin Franklin, Berlin, Germany $u German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany $u Berlin Institute of Health (BIH), Berlin, Germany $u Friede Springer Cardiovascular Prevention Center at Charité, Berlin, Germany $1 https://orcid.org/0000000256463237
700    1_
$a Li, Xinmin S $u Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA
700    1_
$a Wu, Yuping $u Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA $u Department of Mathematics and Statistics, Cleveland State University, Cleveland, OH, USA
700    1_
$a Saha, Prasenjit Prasad $u Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA
700    1_
$a Demuth, Ilja $u Department of Endocrinology and Metabolism, Charité-Universitätsmedizin Berlin, Berlin, Germany $u Berlin Institute of Health Center for Regenerative Therapies, Berlin, Germany $1 https://orcid.org/0000000243402523
700    1_
$a König, Maximilian $u Department of Endocrinology and Metabolism, Charité-Universitätsmedizin Berlin, Berlin, Germany
700    1_
$a Steinhagen-Thiessen, Elisabeth $u Department of Endocrinology and Metabolism, Charité-Universitätsmedizin Berlin, Berlin, Germany
700    1_
$a Cajka, Tomas $u West Coast Metabolomics Center, University of California, Davis, CA, USA $u Institute of Physiology of the Czech Academy of Sciences, Prague, Czech Republic $1 https://orcid.org/0000000297283355 $7 ola2006357540
700    1_
$a Fiehn, Oliver $u West Coast Metabolomics Center, University of California, Davis, CA, USA $1 https://orcid.org/0000000262618928
700    1_
$a Landmesser, Ulf $u Department of Cardiology, Angiology and Intensive Care, German Heart Center of Charité, Campus Benjamin Franklin, Berlin, Germany $u German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany $u Berlin Institute of Health (BIH), Berlin, Germany $u Friede Springer Cardiovascular Prevention Center at Charité, Berlin, Germany $1 https://orcid.org/0000000202143203
700    1_
$a Tang, W H Wilson $u Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA $u Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA $1 https://orcid.org/000000028335735X $7 xx0100943
700    1_
$a Hazen, Stanley L $u Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA. hazens@ccf.org $u Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA. hazens@ccf.org $1 https://orcid.org/0000000171246639
773    0_
$w MED00003459 $t Nature medicine $x 1546-170X $g Roč. 29, č. 3 (2023), s. 710-718
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36849732 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425140952 $b ABA008
999    __
$a ok $b bmc $g 1924526 $s 1190127
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 29 $c 3 $d 710-718 $e 20230227 $i 1546-170X $m Nature medicine $n Nat Med $x MED00003459
GRA    __
$a P01 HL147823 $p NHLBI NIH HHS $2 United States
GRA    __
$a R01 HL103866 $p NHLBI NIH HHS $2 United States
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Možnosti archivace